reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.
Introduced
Moved
Reached a final decision
Became law
Derived from the official record below.
Officially: “reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.” Read the full text
Official title shown verbatim from the official record. Plain-language summary coming as coverage deepens. Not legal advice.
2026 session
Where it is
First read in House and referred to · Jan 21, 2026
Scheduled for hearing · Feb 5, 2026
Health and Human Services
Do Pass · Feb 5, 2026
Health and Human Services
Do Pass · Feb 9, 2026
First read in Senate and referred to · Feb 10, 2026
Scheduled for hearing · Feb 25, 2026
Health and Human Services
Do Pass · Feb 25, 2026
Health and Human Services
Certified uncontested, placed on consent · Feb 25, 2026
Health and Human Services
Remove from Consent Calendar · Feb 26, 2026
Do Pass · Mar 2, 2026
Signed by the Speaker · Mar 3, 2026
Signed by the President · Mar 4, 2026
Delivered to the Governor · Mar 5, 2026
Signed by the Governor · Mar 10, 2026
The numbers
0
sponsors on the bill
Recorded votes
Do PassSenate · 2026-03-02 · yeas 21, nays 12, excused 2, absent 0, present 0, notVoting 0
Do PassSenate · 2026-02-25 · yeas 6, nays 0, excused 1, absent 0, present 0, notVoting 0
Do PassHouse · 2026-02-09 · yeas 58, nays 7, excused 5, absent 0, present 0, notVoting 0
Do PassHouse · 2026-02-05 · yeas 13, nays 0, excused 0, absent 0, present 0, notVoting 0
Roll-call results shown verbatim from the South Dakota legislature’s records. A result reflects that roll call’s own motion, not the bill’s overall outcome.
Every fact on this page links to its source, starting with the official bill record. Last action: Signed by the Governor (Mar 10, 2026).